Driving Innovation And Strategic Excellence in the Life Sciences

www.ventac-partners.com

Why Ventac For Your Life Science Company?

2

• Real-World Operational Experience• Corporate Strategies• New Business Models

• Market & IP Research• Competitive & Pipeline Analysis• Start-ups, spin-outs and early stage

• Due Diligence• Business Development• Product Development Planning

We Bring Real-World, Current Experience To Address Your Analytical And Operational NeedsWe Bring Real-World, Current Experience To Address Your Analytical And Operational Needs

2

Real-World Experience

We Start And Operate New Life Science Companies

Innovation

Venture Capital

Management

• Ventac Partners identifies early-stage assets and technologies from academic and corporate sources• Hundreds of opportunities are reviewed before settling on the best ones with the greatest chance of success

• Ventac Partners creates a new company which licenses the technology• Ventac Partners prepares the business plan and obtains seed funding from investors

• Ventac Partners creates a 2-4 person management team who work for company for equity and low monthly fees• Efficient model means investment is focused on product development, not salaries nor expensive labs/offices

We Start And Build Companies Via A Cost-effective Operational ModelWe Start And Build Companies Via A Cost-effective Operational Model

4

Practicing What We Preach

• We perform market opportunity assessments for our own portfolio opportunities and build data-rich business cases.

• We run out-licensing and fund-raising processes for our portfolio companies…we know what investors and partners are seeking.

• We manage our own companies, so our management and turn-around experiences are real, current, and effective.

Our Advice Is Legitimate Because We Start And Operate Our Own CompaniesOur Advice Is Legitimate Because We Start And Operate Our Own Companies

5

Market Research

Market Research: Foundation For Everything We DoWe Deploy GlobalData And Other Tools For Market ResearchWe Deploy GlobalData And Other Tools For Market Research

7

• Competitive Intelligence Analysis• Disease area strategy and treatment dynamics• Market Assessment• Pipeline landscape analysis• Epidemiology assessments• KOL interviews• Product SWOT and Opportunity Analysis

Always Focused on Value Creation

8

• Commercial Validation• We evaluate commercial opportunities for early-stage assets• Primary and secondary research to build business case• Supported by industry and investment community feedback

• Business Creation• We build the business plan, fundraise and execute, focusing on value creation• We facilitate new company formation, partnering and out-licensing to industry• Our direct experience makes this possible

• Training• We can provide training for management and entrepreneurs• Commercialization, licensing, valuation, patent strategies and company formation• Based on real-world, current information and experiences

8

We Leverage Our Experiences To Develop The Business StrategyWe Leverage Our Experiences To Develop The Business Strategy

Business Development & Related Services

We Serve Investors And Their Companies

• We can provide independent, second opinions on valuations, product and market opportunities, and competitive intelligence

• We run out-licensing and fund-raising processes for our portfolio companies…we know what investors and partners are seeking.

• We can advise portfolio companies on product development plans, from Preclinical through Phase IV.

We Work With Investors And Portfolio Companies On A Daily BasisWe Work With Investors And Portfolio Companies On A Daily Basis

10

We Understand The Need To Drive Towards Exits• Founded 2003• Partnerships with Enzon, GSK, Wyeth, Shire• Acquired for $250 million upfront and an additional contingent payments of $200 million• Danish operations to be renamed Roche Innovation Center Copenhagen

The Recent Acquisition Of Santaris By Roche Provided An Attractive Exit For Ventac And InvestorsThe Recent Acquisition Of Santaris By Roche Provided An Attractive Exit For Ventac And Investors

11

Partners Selected Track RecordFinancing * M&A *

$200,000,000

Strategic Alliance & License

2006

Licensing *

$900,000,000 $380,000,000

2009

$11,500,000

2013

$58,500,000

2010

$500,000,000

2011$917,000,000

2013

$50,000,000

2006

$450,000,000

Acquisition by

2014

$7,500,000

Merged with

2003

*Including transaction completed by partners before joining Ventac Partners

$21,800,000

2013

$348,000,000

2013$1,800,000,000

2013

Strategic Alliance & License

Strategic Alliance & License

Strategic Alliance & License

Strategic Alliance & License

Strategic Alliance & License

Strategic Alliance & LicenseStrategic Alliance & License

Strategic Alliance & License Strategic Alliance & License

Strategic Alliance & License

Series B

2007

2008

$30,000,000

2007$14,000,000

2012

F-1 Prepared

2014

Series C

Preparation for IPO at NASDAQDual Track / M&A by RocheSeries D

$Not disclosed

2007

Co-ownership & LicenseProfessor Imanishi &

Pantheco

$Not disclosed

Acquisition of 8 drugs

2013

$6,700,000

2012

Strategic Alliance & License

$10,000,000

2000

Private Placement to a consortium of Nordic InvestorsLead Manager

$13,000,000

2001

Private Placement to a consortium of Nordic InvestorsSole Manager

$Not disclosed

2000

Worldwide rights to LNA technology

$180,000,000

2000

Worldwide semi-exlusive manufacturing rights to LNA technology

$Not disclosed

2000

Use of LNA in clinical diagnostics

$23,000,000

2004

$10,500,000

2006

$17,000,000

2003

Series BPrivate Financing

Series CPrivate FinancingPrivate Financing

$400,000,000

2005

Strategic Alliance &License

$4,000,000

2014

Series A

$10,300,000

2006

Series A (2nd closing)

$47,000,000

2009

Series B

$35,000,000.

2000

Novartis Research FoundationPartnership

$Not disclosed

Merged with

2014

$Not disclosed

Acquisition of

2014

$700,000,000

2007

$Not disclosed

2009-2015

$10,000,000

2010-2014

$Not disclosed

2004

$Not disclosed

2008

Raises Seed Funds&Series A & B financingStrategic Alliance &License Strategic Alliance &License

Raises Seed Funds&Series A, B & C financing

$2,100,000

2015

Listing on SwedishStock Exchange

$Not disclosed

2011

$Not disclosed

Strategc Alliance &License

2011

Miacom Diagnostics

We’ve done it before…We’ve done it before…

Our Team

21 Partners and 14 offices on 3 Continents

Lund CopenhagenBaselMadrid

Hong Kong

Boulder Boston MunichHelsinki

ViennaDüsseldorf

ShanghaiNew York

We Work Where You Do – And Provide Global ReachWe Work Where You Do – And Provide Global Reach

19

San Francisco(2016)

London

15

Our International Team

Driving Innovation And Strategic Excellence in the Life Sciences

www.ventac-partners.com